{"id":"W2789541411","doi":"10.1177/2045125318762365","title":"Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial","year":2018,"lang":"en","type":"article","venue":"Therapeutic Advances in Psychopharmacology","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"NOSM University","funders":"Cilag; Health Technology Assessment Programme; H. Lundbeck A/S; Otsuka Pharmaceutical; Amicus Therapeutics; National Institute for Health and Care Research; Sunovion; Eli Lilly and Company","keywords":"Amisulpride; Clozapine; Positive and Negative Syndrome Scale; Tolerability; Placebo; Adverse effect; Medicine; Scale for the Assessment of Negative Symptoms; Internal medicine; Randomized controlled trial; Antipsychotic; Atypical antipsychotic; Schizophrenia (object-oriented programming); Psychology; Psychiatry; Psychosis; Brief Psychiatric Rating Scale","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003327074,0.0003181788,0.0009335831,0.0004183663,0.00009151531,0.000008182188,0.0001560529,0.0001474249,0.0005757308],"category_scores_gemma":[0.00002817686,0.0002385723,0.0002564018,0.0003295516,0.0003563318,0.0001705132,0.00001721468,0.0001365493,0.00003884534],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003087743,"about_ca_system_score_gemma":0.0003532563,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002203449,"about_ca_topic_score_gemma":0.0001531288,"domain_scores_codex":[0.9978805,0.0001609094,0.0007037335,0.0004892688,0.0002661211,0.0004994714],"domain_scores_gemma":[0.9984857,0.0005447068,0.0002957374,0.0003134157,0.0001915967,0.0001688548],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.851134,0.002168611,0.00008745415,0.00003963722,0.0007166441,0.00001276442,0.0001593633,0.000007128555,0.01121235,0.0004813609,0.0000356354,0.133945],"study_design_scores_gemma":[0.9605396,0.01622301,0.0001820883,0.00002994517,0.0005793927,0.00001514257,0.00006169293,0.0002706773,0.01118586,0.002348507,0.008398533,0.0001655312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.975338,0.009953192,0.0008626719,0.0008064671,0.001670502,0.01053928,0.00001956064,0.0000610452,0.0007493208],"genre_scores_gemma":[0.9846569,0.005596668,0.003115246,0.000287519,0.001087,0.004659662,0.00005020196,0.00004459578,0.0005022218],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1337795,"threshold_uncertainty_score":0.9728695,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0536004326467893,"score_gpt":0.4385091208658433,"score_spread":0.384908688219054,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}